Oxidative Inactivation of Paraoxonase1, an Antioxidant Protein and its Effect on Antioxidant Action

References

• La Du, B.N. (1996) "Structural and functional diversity of paraoxonase", Nat. Med. 2, 1186–1187.
   PubMed Web of Science ®Google Scholar
• Berliner, J.A., Navab, M., Fogelman, AM., Frank, J.S., Demer, L.L., Edwards, PA., Watson, AD. and Lusis, A.J. (1995) "Atherosclerosis: basic mechanism, oxidation, inflammation and genetics", Circulation 91, 2488–2496.
   PubMed Web of Science ®Google Scholar
• Mackness, MI., Mackness, B., Durrington, P.A., Connelly, P.W. and Hegele, R.A. (1996) "Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins", Curr. Opin. Lipidol. 7, 69–76.
   PubMed Web of Science ®Google Scholar
• Davies, HG., Richter, R.J., Keifer, M., Broomfield, CA., Sowalla, J. and Furlong, C.E. (1996) "The effect of the human serum paraoxonase polymorphism is reversed with dia-zoxon, soman and sarin", Nat. Genet. 14, 334–336.
   PubMed Web of Science ®Google Scholar
• Gan, K.N., Smolen, A., Eckerson, H.W. and La Du, B.N. (1991) "Purification of human serum paraoxonase/arylesterase", Drug Metab. Dispos. 19, 100–106.
   PubMed Web of Science ®Google Scholar
• Jakubowski, H. (2000) "Calcium-dependent human serum homocysteine thiolactone hydrolase: a protective mechanism against protein N-homocysteinylation", J. Biol. Chem. 275, 3957–3962.
   PubMed Web of Science ®Google Scholar
• Josse, D., Loduidge, 0., Xie, W., Bartels, C.F., Schopfer, L.M. and Masson, P. (2001) "The active site of human paraoxonase (PON1)", J. Appl. Toxicol. 21, S7—S11.
   Web of Science ®Google Scholar
• Shih, D.M., Cu, L., Xia, Y-R., Navab, M., Li, W.-F., Hama, S., Castellani, LW., Furlong, CE., Costa, L.G., Fogelman, AM. and Lusis, A.J. (1998) "Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis", Nature 394, 284–287.
   PubMed Web of Science ®Google Scholar
• Ferguson, E., Parthasarathy, S., Joseph, J. and Kalyanaraman, B. (1998) "Generation and initial characterization of a novel polyclonal antibody directed against homocysteine thiolactone-modified low density lipoprotein", J. Lipid Res. 39, 925–933.
   PubMed Web of Science ®Google Scholar
• Watson, AD., Berliner, J.A., Hama, S.Y., La Du, B.N., Fauli, K.F., Fogelman, A.M. and Mohamad, N. (1995) "Protective effect of high density lipoprotein associated paraoxnase: inhibition of the biological activity of minimally oxidized low density lipoprotein", J. Clin. Investig. 96, 2882–2891.
   PubMed Web of Science ®Google Scholar
• Aviram, M., Rosenblat, M., Billecke, S., Erogul, J., Sorenson, R., Bisgaier, CI., Newton, R.S. and La Du, B.N. (1999) "Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by anti-oxidants", Free Radic. Biol. Med. 26, 892–904.
   PubMed Web of Science ®Google Scholar
• Ahmed, Z., Ravandi, A., Maguire, C.F., Emili, A., Draganov, D., La Du, B.N., Kuksis, A. and Connelly, P.W. (2001) "Apolipoprotein A-I promotes the formation of phospha-tidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor", J. Biol. Chem. 276, 24473–24481.
   PubMed Web of Science ®Google Scholar
• Aviram, M., Hardak, E., Vaya, J., Mahmood, S., Milo, S., Hoffman, A., Billicke, S., Draganov, D. and Rosenblat, M. (2000) "Human serum paraoxnase (PON 1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and pero)d-dase-like activities", Circlulation 101, 2510–2517.
   PubMed Web of Science ®Google Scholar
• Ahmed, Z., Ravandi, A., Maguire, C.F., Emili, A., Draganov, D., La Du, B.N., Kuksis, A. and Connelly, P.W. (2002) "Multiple substrates for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite", Biochem. Biophys. Res. Commun. 290, 391–396.
   PubMed Web of Science ®Google Scholar
• Aviram, M., Billecke, S., Sorenson, R., Bisgaier, C., Newton, R., Rosenblat, M., Erogut J., Hsu, C., Dunlop, C. and La Du, B.N. (1998) "Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/para-oxonase activities", Arterioscler. Thromb. Vasc. Biol. 18, 1617–1624.
   Google Scholar
• Shih, D.M., Cu, L., Hama, S., Xia, Y.-R., Navab, M., Fogelman, A.M. and Lusis, A.J. (1996) "Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model", J. Clin. Investig. 97, 1630–1639.
   PubMed Web of Science ®Google Scholar
• Ruiz, J., Blanche, H., James, R.W., Garin, MC., Vaisse, C., Charpentier, G., Cohen, N., Morabia, A., Passa, P and Froguel, P. (1995) "Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes", Lancet 30, 869–872.
   Google Scholar
• Mackness, B., Davies, G.K., Turkie, W., Lee, E., Roberts, D.H., Hill, E., Roberts, C., Durrington, P.N. and Mackness, MI. (2001) "Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?", Arterioscler. Thromb. Vasc. Biol. 21, 1451–1457.
   PubMed Web of Science ®Google Scholar
• Mackness, B., Durrington, P.N. and Mackness, M.I. (2002) "The paraoxonase gene family and coronary heart disease", Curr. Opin. Lipidol. 13, 357–362.
   PubMed Web of Science ®Google Scholar
• Furlong, CE., Cole, TB., Jarvik, G.P. and Costa, L.G. (2002) "Pharmacogenomic considerations of the paraoxonase poly-morphisms", Pharmacogenomics 3, 341–348.
   PubMed Web of Science ®Google Scholar
• Rodrigo, L., Mackness, B., Durrington, P.N., Hernandez, A. and Mackness, MI. (2001) "Hydrolysis of platelet-activating factor by human serum paraoxonase", Biochem. J. 354, 1–7.
   PubMed Web of Science ®Google Scholar
• Marathe, G.K., Zimmerman, GA. and McIntyre, T.M. (2003) "PAF acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein par-ticles", J. Biol. Chem. 278, 3937–3947.
   PubMed Web of Science ®Google Scholar
• Berliner, J.A. and Heinecke, J.W. (1996) "The role of oxidized lipoproteins in atherogenesis", Free Radic. Biol. Med. 20, 707–727.
   PubMed Web of Science ®Google Scholar
• Burkitt, M.J.A. (2001) "Critical overview of the chemistry of copper-dependent low density lipoprotein oxidation: roles of lipid hydropermddes, alpha-tocopherol, thiols, and cerulo-plasmin", Arch. Biochem. Biophys. 394, 117–135.
   PubMed Web of Science ®Google Scholar
• Ferretti, G., Bacchetli, T., Marchionni, C., Caldarelli, L. and Curatola, G. (2001) "Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity", Acta Diabetol. 38, 163–169.
   PubMed Web of Science ®Google Scholar
• McCall, M.R., Tang, J.Y., Bielicki, J.K. and Forte, T.M. (1995) "Inhibition of lecithin-cholesterol acyltransferase and modi-fication of HDL apolipoproteins by aldehydes", Art erioscler. Thromb. Vasc. Biol. 15, 1599–1606.
   PubMed Web of Science ®Google Scholar
• Bub, A., Barth, S., Watzl, B., Briviba, K., Herbert, B.M., Luhrmann, P.M., Neuhauser-Berthold, M. and Rechkemmer, G. (2002) "Paraoxonase 1 Q192R (PON1-192) polymorphism is associated with reduced lipid permddation in R-allele-carrier but not in QQ homozygous elderly subjects on a tomato-rich diet", Fur. J. Nutr. 41, 237–243.
   Web of Science ®Google Scholar
• Liu, T.-Y. and Chang, Y.H. (1971) "Hydrolysis of proteins with p-toluenesulfonic acid", J. Biol. Chem. 246, 2842–2848.
   PubMed Web of Science ®Google Scholar
• Tarr, G.E. (1986) In: Shively, J.E., ed, Methods of protein microcharacterization (Humana Press, Clifton, NJ), pp 155–194.
   Google Scholar
• Ellman, GI. (1958) "A colorimetric method for determining low concentrations of mercaptans", Arch. Biochem. Biophys. 74, 443–450.
   PubMed Web of Science ®Google Scholar
• Halliwell, B., Gutteridge, J.M. and Aruoma, 0.1. (1987) "The deoxyribose method: a simple test-tube assay for determi-nation of rate constants for ractions od hydroxyl radicals", Anal. Biochem. 165, 215–219.
   Web of Science ®Google Scholar
• Puppo, A. and Halliwell, B. (1989) "Oxidation of dimethyl-sulphoxide to formaldehyde by oxyhaemoglobin and oxyleghaemoglobin in the presence of hydrogen peroxide is not mediated by free hydroxyl radicals", Free Radic. Res. Commun. 5, 277–281.
   PubMedGoogle Scholar
• Bray, T.M. and Bettger, W.J. (1990) "The physiological role of zinc as an antioxidant", Free Radic. Biol. Med. 8, 281–291.
   PubMed Web of Science ®Google Scholar
• Sok, D.-E. (1998) "Ascorbate-induced oxidative inactivation of Zn2±-glycerophos-phocholine cholinephosphodiesterase", J. Neurochem. 70, 1167–1174.
   PubMed Web of Science ®Google Scholar
• Esterbauer, H., Schaur, R. and Zollner, H. (1991) "Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes", Free Radic. Biol. Med. 11, 81–128.
   PubMed Web of Science ®Google Scholar
• Uchida, K. and Stadtman, KR. (1992) "Selective cleavage of thioester linkage in proteins modified with 4-hydroxynone-nal", Proc. Natl. Acad. Sci. USA 89, 5611–5615.
   PubMed Web of Science ®Google Scholar
• Levine, R.L., Oliver, C.N., Fulko, R.M. and Stadtman, E.R. (1981) "Turnover of bacterial glutamine synthetase: oxidative inactivation proceeds proteolysis", Proc. Natl. Acad. Sci. USA 78, 2120–2124.
   PubMed Web of Science ®Google Scholar
• Halliwell, B. and Gutteridge, J.M. (1984) "Oxygen toxicity, oxygen radicals, transition metals and disease", Biochem. J. 219, 1–14.
   PubMed Web of Science ®Google Scholar
• Stadtman, E.R. and Oliver, C.N. (1991) "Metal-catalyzed oxidation of proteins", J. Biol. Chem. 266, 2005–2008.
   PubMed Web of Science ®Google Scholar
• Swain, J. and Gutteridge, J.M.C. (1995) "Prooxidant iron and copper with ferroxidase and xanthine mddase activities in human atherosclerosis", FEBS Lett. 368, 513–515.
   PubMed Web of Science ®Google Scholar
• Jialal, I., Vega, G.L. and Grundy, S.M. (1990) "Physiologic levels of ascorbate inhibit the oxidative modification of low density lipoprotein", Atherosclerosis 82, 185–191.
   PubMed Web of Science ®Google Scholar
• Minqin, R., Watt, F., Huat, B.T. and Halliwell, B. (2003) "Correlation of iron and zinc levels with lesion depth in newly formed atherosclerotic lesions", Free Radic. Biol. Med. 34, 746–752.
   PubMed Web of Science ®Google Scholar
• Doom, J.A., Sorenson, R.C., Billecke, S.S., Hsu, C. and La Du, B.N. (1999) "Evidence that several conserved histidine residues are required for hydrolytic activity of human paraoxonase /arylesterase", Chem.-Biol. Interact. 119–120, 235–241.
   PubMed Web of Science ®Google Scholar
• Uchida, K. and Kawakishi, S. (1990) "Site-specific oxidation of angiotensin I by copper(II) and L-ascorbate: conversion of histidine residues to 2-imidazolones", Arch. Biochem. Biophys. 283, 20–26.
   PubMed Web of Science ®Google Scholar
• Uchida, K. and Kawakishi, S. (1993) "2-0xo-histidine as a novel biological marker for mddatively modified proteins", FEBS Lett. 332, 208–210.
   PubMed Web of Science ®Google Scholar
• Josse, D., Xie, W., Renault, F., Rochu, D., Schopfer, L.M., Masson, P. and Lockridge, 0. (1999) "Identification of residues essential for human paraoxonase (PON1) arylesterase/organophosphate activities", Biochemistry 38,2816–2825.
   Google Scholar
• Benedetti, A., Comporti, M. and Esterbauer, H. (1980) "Identification of 4-hydroxynonenal as a cytotoxic product originating from the permddation of liver microsomal lipids", Biochim. Biophys. Acta 620, 281–296.
   PubMed Web of Science ®Google Scholar
• Draganov, DJ., Stetson, Pi., Watson, CE., Billecke, S.S. and La Du, B.N. (2000) "Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation", J. Biol. Chem. 275, 33435–33442.
   PubMed Web of Science ®Google Scholar
• Maor, L., Hayek, T., Coleman, R. and Aviram, M. (1997) "Plasma LDL oxidation leads to its aggregation in the atherosclerotic apolipoprotein E-deficient mice", Art erioscler. Thromb. Vasc. Biol. 17, 2995–3005.
   PubMed Web of Science ®Google Scholar
• Rozenberg, 0., Rosenblat, M., Coleman, R., Shih, D.M. and Aviram, M. (2003) "Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice", Free Radic. Biol. Med. 15, 774–784.
   PubMed Web of Science ®Google Scholar
• Jaouad, L., Milochevitch, C. and Khalil, A. (2003) "PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity", Free Radic. Res. 37, 77–83.
   PubMed Web of Science ®Google Scholar
• Kuremoto, K., Watanabe, Y, Ohmura, H., Shimada, K., Mokuno, H. and Daida, H. (2003) "R/R Genotype of human paraoxonase (PON1) is more protective against lipoprotein oxidation and coronary artery disease in Japanese subjects", J. Atheroscler. Thromb. 10, 85–92.
   PubMedGoogle Scholar